Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Strategies to Address Antibiotic Resistance Act or the STAAR Act This bill amends the Public Health Service Act to revise provisions regarding the Antimicrobial Resistance Task Force. The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria must provide advice, information, and recommendations to the Department of Health and Human Services. The Centers for Disease Control and Prevention (CDC) must carry out activities to collect data on antibiotic resistance, including assessing conditions and outcomes related to antibacterial resistance and working with others to obtain human antibiotic drug consumption data. The CDC must establish Antibiotic Resistance Surveillance and Laboratory Network sites, including to monitor antibiotic-resistant bacteria, describe and respond to outbreaks, and evaluate resistance testing methods. The National Institute of Allergy and Infectious Diseases must maintain: (1) a Clinical Trials Network on Antibacterial Resistance, and (2) a leadership group to advance a clinical research agenda to address antibacterial resistance. The CDC must work with state and local health departments to support efforts by groups of health care facilities to prevent the spread of antibiotic-resistant bacteria. The CDC and the epicenters participating in the Prevention Epicenters Program must work with others to: (1) evaluate prevention programs and interventions to limit infections in health care facilities, and (2) facilitate research on the prevention and control of resistant organisms. The CDC must use research from the epicenters to create and disseminate educational materials for use in health care facilities.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2016 · fourth_quarter · Health Issues
Hospital Group Purchasing Organizations - Provided ongoing outreach and education efforts regarding the value delivered by group purchasing organizations for hospitals across the country. Drug Prices - (S. 2615 - the Increasing Competition in Pharmaceuticals Act) Supported passage of S. 2615. Monitored legislative proposals to slow the growth of increasing prices in prescription drugs. Tracked ongoing discussion and offered information relating to how hospital group purchasing organizations help hold down cost growth of prescription drugs. 340B Drug Discount Program - Monitored proposals to modify the 340B Drug Discount program. 21st Century Cures (H.R. 6, H.R. 34) - Supported enhancing funding and improving efficiency within the Food and Drug Administration and the National Institutes of Health in the 21st Century Cures Act. Supported inclusion of funding for programs authorized under the Comprehensive Addiction and Recovery Act to address growing challenges related to opioid abuse and addiction. Supported provisions related to combating drug resistant bacteria included in the 21st Century Cures Act. Stark Law Reform - Monitored discussions in the Senate Finance Committee around potential changes to Stark laws. Advocated for changes to the Stark laws to allow hospitals and other providers to work together to reduce costs in health care. Anti-microbial stewardship (S. 3176 - the Strategies to Address Antibiotic Resistance Act; S. 2467 - the Patient Safety Improvement Act) - Engaged in education and outreach efforts to highlight the importance of antimicrobial stewardship.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $125,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Hospital Group Purchasing Organizations - Provided ongoing outreach and education efforts regarding the value delivered by group purchasing organizations for hospitals across the country. Drug Prices - (S. 2615 - the Increasing Competition in Pharmaceuticals Act) Supported passage of S. 2615. Monitored legislative proposals to slow the growth of increasing prices in prescription drugs. Tracked ongoing discussion and offered information relating to how hospital group purchasing organizations help hold down cost growth of prescription drugs. 340B Drug Discount Program - Monitored proposals to modify the 340B Drug Discount program. 21st Century Cures (H.R. 6) - Tracked the development of Senate counterpart to the House-passed 21st Century Cures legislation and raised concerns about potential offsets that could impact hospital payments. Opioid legislation (S. 524, the Comprehensive Addiction and Recovery Act) - Supported passage of legislation to address growing challenges related to opioid abuse and addiction. Zika Virus (H.R. 5325 -Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act) - Monitored ongoing debate around legislative packages to provide funding to combat the spread of the Zika Virus. Stark Law Reform - Monitored discussions in the Senate Finance Committee around potential changes to Stark laws. Advocated for reasonable changes to the Stark laws to allow hospitals and other providers to work together to reduce costs in healthcare. Anti-microbial stewardship (S. 3176 - the Strategies to Address Antibiotic Resistance Act; S. 2467 - the Patient Safety Improvement Act) - Engaged in education efforts to highlight the work Vizient is doing to combat antibiotic resistance.
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Agriculture
Discussions with Congressional staff regarding the use of antimicrobials in food-producing animals, particularly with respect to FDA's strategy and VFD Rule and S. 3176, Strategies to Address Antibiotic Resistance Act H.R. 5054/S. 2956, Fiscal Appropriations including Agriculture Appropriations
Client expense: $200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE